The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

According to a recent report by CIDRAP and the CDC, published on November 24, 2025, viral activity is on the rise, and it's ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

The preventive therapies would be the latest called into question under U.S. Health Secretary Robert F. Kennedy Jr., a long-time promoter of anti-vaccine views.

Key Takeaways The U.S. Food and Drug Administration is reviewing two RSV drugs for infantsNo safety issues have been ...

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...